Regeneron's drug becomes first FDA-approved Ebola virus treatment


By Deena Beasley

(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals' triple antibody cocktail as the first Ebola treatment, lending validation to similar drugs being developed for COVID-19.

Regeneron's Inmazeb, an intravenous drug, has been approved for adults and children, after it was tested in 382 candidates with confirmed Zaire ebolavirus infection in a clinical trial, the health regulator said.

The drugmaker has said it is talking with the FDA about an emergency use authorization for its experimental dual antibody cocktail for COVID-19, which was given to U.S. President Donald Trump as part of his treatment regime.

The treatments are part of a class of drugs known as monoclonal antibodies, which are manufactured copies of antibodies that are one of the main weapons generated by the immune system to fight infections.

"Today's action demonstrates the FDA's ongoing commitment to responding to public health threats — both domestically and abroad — on the basis of science and data," FDA Commissioner Stephen Hahn said in a media statement.

The FDA approved Ervebo, the first vaccine for the prevention of Ebola virus disease, in December 2019.

Related Articles

Survey probes U.S. adults' willingness to accept COVID-19 vaccine

By Will Boggs MD NEW YORK (Reuters Health) - A national survey that probed U.S. adults' likelihood of accepting a COVID-19 vaccine found efficacy was the most important attribute, with longer Read More »

U.S. reports about 300,000 more deaths than usual during pandemic - CDC

By Vishwadha Chander (Reuters) - Nearly 300,000 more people have died in the United States in 2020 during the coronavirus pandemic than expected based on historical trends, with about two-thirds of Read More »

CORRECTED-Mexico could absorb some COVID-19 vaccine liabilities

(Corrects headline and paragraph 1 to correct that government to accept some, not all liabilities) By Anthony Esposito and Adriana Barrera MEXICO CITY (Reuters) - Mexico's government could absorb some Read More »

© 2020 /alert® unless otherwise noted. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
Privacy Policy | Terms of Use
Do Not Sell My Personal Information